galderma articles ↓

A recently posted clinical trial suggests that Taro Pharmaceuticals is readying to gain approval to market Generic Metrogel 1%. Currently Generic Metrogel is only available in 0.75% strength. Taro Pharmaceuticals in fact already markets a generic form of Metrogel – Metronidazole Gel USP, 0.75% When the patent covering Metrogel 0.75% expired, Galderma changed the formulation, increased the concentration of metronidazole to 1% …

While us in the rosacea world might consider products that are expensive while they are covered by exclusive patents, we are small fry in the drug market at large.

Patents are due to shortly expire for Pfizer’s Liptor and Lilly’s Zyprexa. Lilly can expect a $3bn drop in revenue just from generic forms  of Zyprexa becoming available. Pfizer is thought to have earned around $7.8bn from …

Galderma has another rosacea-targeted treatment, until now undisclosed, in the final stages of approval. Hey – how come no one told me?

Could it be possible that the rosacea heavyweight Galderma has kept a new product so secret?
What is this CD5024?
Just what exactly is this CD5024 1% Cream? Galderma …

Some news today from the Phase 2B Sansrosa Trials;

Galderma is now confirming that during the 8 week trial, participants did not suffer from tachyphylaxis or rebound.

This means that if you stop and start sanrosa or continue to use it for an extended period you likely won’t suffer from a rebound effect or from a reduced effectiveness.

This is some good news as it indicates the formulation …

A recently updated patent application by Galderma shows that they want to reserve the right to create a Metronidazole Foam product.

Galderma has a long history with topical metronidazole products, starting with Metrogel 0.75%, then adding Metrolotion and Metrocream, and when the patent on the 0.7% Metrogel expired, Galderma created Metrogel 1%.

Past research seems to suggest that it matters little whether you use Metrogel, Metrolotion, …